Cargando…

Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy

Cancer immunotherapy is impaired by the intrinsic and adaptive immune resistance. Herein, a bispecific prodrug nanoparticle was engineered for circumventing immune evasion of the tumor cells by targeting multiple immune resistance mechanisms. A disulfide bond-linked bispecific prodrug of NLG919 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Jiayi, Hou, Bo, Chen, Fangmin, Zhang, Shunan, Xiong, Muya, Li, Tianliang, Xu, Yechun, Xu, Zhiai, Yu, Haijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214055/ https://www.ncbi.nlm.nih.gov/pubmed/35755274 http://dx.doi.org/10.1016/j.apsb.2021.09.021

Ejemplares similares

Dual-targeting prodrug nanotheranostics for NIR-Ⅱ fluorescence imaging-guided photo-immunotherapy of glioblastoma
por: Li, Fenglin, et al.
Publicado: (2022)

Self‐Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer
por: Zhu, Yun, et al.
Publicado: (2022)

Regulating Glucose Metabolism with Prodrug Nanoparticles for Promoting Photoimmunotherapy of Pancreatic Cancer
por: Sun, Fang, et al.
Publicado: (2021)

Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer
por: Hu, Xianli, et al.
Publicado: (2020)

Engineering Prodrug Nanomedicine for Cancer Immunotherapy
por: Yang, Bin, et al.
Publicado: (2020)

Circumventing the Greatwall
por: Short, Ben
Publicado: (2014)

Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
por: To, Kenneth K. W., et al.
Publicado: (2023)

In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease
por: Xiong, Muya, et al.
Publicado: (2022)

Unraveling the catalytic mechanism of SARS-CoV-2 papain-like protease with allosteric modulation of C270 mutation using multiscale computational approaches
por: Shao, Qiang, et al.
Publicado: (2023)

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Glutathione‐Responsive Nanoparticles of Camptothecin Prodrug for Cancer Therapy
por: Zhang, Lingpu, et al.
Publicado: (2022)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

Bispecific antibodies come to the aid of cancer immunotherapy
por: Amelio, Ivano, et al.
Publicado: (2021)

Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy
por: Zhou, Mengxue, et al.
Publicado: (2023)

Microenvironment‐Responsive Prodrug‐Induced Pyroptosis Boosts Cancer Immunotherapy
por: Xiao, Yao, et al.
Publicado: (2021)

Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy
por: Ma, Xianbin, et al.
Publicado: (2022)

Circumventing AKT-Associated Radioresistance in Oral Cancer by Novel Nanoparticle-Encapsulated Capivasertib
por: Lang, Liwei, et al.
Publicado: (2020)

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy
por: Zhou, Shu-juan, et al.
Publicado: (2017)

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
por: You, Gihoon, et al.
Publicado: (2021)

Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
por: Zhou, Yanchen, et al.
Publicado: (2022)

Simultaneous consumption of cellobiose and xylose by Bacillus coagulans to circumvent glucose repression and identification of its cellobiose-assimilating operons
por: Zheng, Zhaojuan, et al.
Publicado: (2018)

Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
por: Gao, Jing, et al.
Publicado: (2022)

Author Correction: Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
por: Gao, Jing, et al.
Publicado: (2022)

Photocatalytic Protein Damage by Silver Nanoparticles Circumvents Bacterial Stress Response and Multidrug Resistance
por: Shi, Tianyuan, et al.
Publicado: (2019)

Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
por: Wang, Feihu, et al.
Publicado: (2020)

Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy
por: Cho, Jaewon, et al.
Publicado: (2022)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022)

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease
por: Wang, Qian, et al.
Publicado: (2023)

Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance
por: Wang, Yongheng, et al.
Publicado: (2021)

Editorial: How to circumvent the tumour-promoting effect of cytokine in tumour therapy
por: Ma, Lingman, et al.
Publicado: (2023)

Biomimetic inorganic camouflage circumvents antibody-dependent enhancement of infection
por: Wang, Xiaoyu, et al.
Publicado: (2017)

Strategies to circumvent the CFTR defect in cystic fibrosis
por: Becq, Frédéric, et al.
Publicado: (2013)

Designing malaria vaccines to circumvent antigen variability()
por: Ouattara, Amed, et al.
Publicado: (2015)

How Dengue Virus Circumvents Innate Immunity
por: Kao, Yu-Ting, et al.
Publicado: (2018)

Potential mechanisms of resistance to venetoclax and strategies to circumvent it
por: Tahir, Stephen K., et al.
Publicado: (2017)

Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma
por: Zou, Jianxuan, et al.
Publicado: (2015)

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
por: Del Bano, Joanie, et al.
Publicado: (2015)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lfk43v4idkdiet0j2ts3h0lm5v